6月3日-6日，2019美國生物学技術大會暨展覽會（2019 Biotechnology Innovation Organization International Convention）在美國賓夕法尼亞州費城舉行，復宏漢霖已经復星醫藥集團惊艳亮相我县大會。
來訪者對復宏漢霖產品管線留下深刻印象
此次大會共吸引了逾1800位參展商以及17300多位全球行業領導者和頂級研究學者，他們在大會上與來自全球的生物製藥公司和醫藥公司共同探索合作共贏的潛在機遇。短短几天，復宏漢霖累計參與了190多場會面，同來自全球的合作商探討了在生物製品治療、技術平台、腫瘤免疫聯合療法等方面建立良好合作關係的可能性。不少合作商對復宏漢霖的產品管線、特別是首個獲批上市的中國國產生物類似葯漢利康®留下了深刻印象。
質高價優的治療方案受人矚目
復宏漢霖展示台吸引住了多家訪問者/組織機構前來拜訪，這中间甚多全国新葯研發組織和前十强臨床探讨機構。復宏漢霖聯合創始人、总裁科學官姜偉東教授代表：「當談及質高價優的治療情况报告時，并没有人不會對之產生興趣。我們之間總能產生思維的相撞，繼而挑战很多持續的創新。」
當被問及復宏漢霖對將在聖地亞哥舉行的2020美國海洋动物体技術大會暨展覽會有哪些盼望的時，復宏漢霖商務扩展副總裁曹平女人说道，通過我司2019美國海洋动物体技術大會暨展覽會，復宏漢霖已與諸多美國和歐洲地區的潛在进行公司合作商组建了较好聯繫，我想2020美國海洋动物体技術大會暨展覽會也會為復宏漢霖繼續探秘世界各国进行公司合作關係供应非常多機會，同時也盼望的2020美國海洋动物体技術大會暨展覽會能回歸加利福尼亞州，復宏漢霖的美國研發中心点也位于於此。
復宏漢霖積極推動全球布局
近两年來，復宏漢霖積極推動各国战略布局。研發上，自20二十年装修工厂的设立以來，復宏漢霖以各国聯動、转型創新為產品開發核心价值，在中國沈阳、大阪和美國加州均設有研發實驗室，具備了兩岸3个地方技術互補的明显優勢。產品上，其另一类再迎產品HLX02（填充用曲妥珠單抗）已相繼在中國大陸、烏克蘭、歐盟波蘭和菲律賓完全啟動國際多基地3期臨床試驗，成為國內首個開展國際多基地3期臨床研究分析的生物学類似葯，現已填写退市申請。憑藉領先的國際質量標準，復宏漢霖已與某些各国領先的醫藥装修工厂的達成戰略商業化企业媒体协议，以透過企业媒体协议夥伴不仅有的水平和資源发展佔有顶级市場份額。復宏漢霖與顶级Accord、Cipla、Biosidus及Jacobson等装修工厂的簽訂了商業企业媒体协议協議，對外授權覆蓋各国82個國家和地區。
未來，復宏漢霖也會持續不断探索更多的國際化合作的已经，在國際化的道道路上繼續秉「質」向前，以優質怪物葯，惠及全球最大病患者！
關於美國生物技術大會暨展覽會
美國怪物体技術大會暨展覽會(BIO International Convention)是全.球极大的怪物体技術行業盛會，众多了來自全.球的業內領先怪物体製藥大单位、投資商及的企业媒体合作商，並有諸多的企业媒体合作活動在大會期間舉行。大會由美國怪物体技術創新組織機構(Biotechnology Innovation Organization，下面簡稱「BIO」) 主辦，是是指怪物体技術大单位、學術機構和相關機構的全.球极大怪物体技術行業協會，其成員覆蓋美國和其他30個國家。BIO秉承於為怪物体技術行業可以提供更多的行業聊天、的企业媒体合作機遇機會。
關於復宏漢霖
成都復宏漢霖微海洋生物工程体技術持股有现我司為一所中國領先的微海洋生物工程体製藥我司，专注于於為全世界女性提高質高價優的創新微海洋生物工程体葯。自20二十年创立以來，我司在中國成都、台北市和美國加州均設有研發管理中心，已經实现並持續全新升级推进改革的微海洋生物工程体類似葯及微海洋生物工程体創新葯產品管線，產品覆蓋腫瘤、自免疫系统性常见疾病等領域。
截至目前，復宏漢霖13個產品、2個聯合治療方案已完成23項適應症的臨床試驗申請，累計獲得全球範圍內29個臨床試驗許可（中國大陸19個，中國台灣3個，美國3個，歐盟、澳大利亞、烏克蘭和菲律賓各1個）。其中，公司首款重磅產品漢利康®（利妥昔單抗注射液）已獲國家葯監局新葯上市註冊批准，成為中國首個獲批上市的生物類似葯。HLX03（阿達木單抗注射液）於2019年1月獲國家葯監局新葯上市申請受理，現已納入優先審評程序。HLX02（注射用曲妥珠單抗）相繼在中國大陸、烏克蘭、歐盟波蘭和菲律賓全面啟動國際多中心3期臨床試驗，成為國內首個開展國際多中心3期臨床研究的生物類似葯，於2019年4月獲國家葯監局新葯上市申請受理。
Henlius Attends BIO 2019
This past week, the Biotechnology Innovation Organization』s 2019 (BIO-2019) International Convention attracted more than 17,300 top biotech innovators, researchers and visionaries across the globe at the Pennsylvania Convention Center in Philadelphia. As one of the 1,800 exhibitors, Shanghai Henlius Biotech, Inc. (Henlius), along with Fosun Pharma (the parent company of Henlius), had an opportunity to connect with many biotechnology and pharmaceutical companies』 leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships at the convention. Through back-to-back scheduled meetings , Henlius ended with more than 190 meetings with national and international partners and multiple possible leads for in-licensing, research collaboration or commercial right out-licensing conducting at the Henlius』 booth over the course of three-day exhibition. These discussions were primarily focused on advancing new approaches to science, including therapeutic biologics, technology platforms, and immuno-oncology combinations, and building robust partnerships to accelerate innovation. A large majority of these potential future partners has confirmed their interest in continuing an in-depth conversion with Henlius after BIO-2019.
Since the first rituximab biosimilar being approved by China National Medical Products Administration (NMPA) on February 22, 2019, Henlius has been recognized as a rising star by many companies worldwide. Attendees who had previously not familiar with Henlius were quite impressed by its pipeline in both biosimilar and bio-innovative antibodies and expressed interests in collaborating with Henlius in a variety of ways. Dr. Weidong Jiang, Chief Scientific Officer and Co-Founder at Henlius, stated that 「there is no shortage of excitement, innovation or ideas, particularly when it comes to affordable and effective treatments」. Jiang agreed, noting that Henlius had a daily flow of 40+ interested visitors and organizations ranging from potential global drug developers to branding Clinical Research Organizations dropping by at the booth.
When Ms. Ping Cao, Vice President of Business Development at Henlius, was asked by the BIO organizer 「what will be the objective for Henlius at the next BIO-2020 in San Diego?」 Ping shared some words of excitement: with many productive meetings accomplished at BIO-2019, Henlius has made connections with a handful of potential collaborations and partnerships especially in the USA and Europe. Henlius purses every opportunity to help patients, caregivers, regulators and the industry as working together to impact affordability of effective treatments. BIO-2020 will be a great opportunity for Henlius to continue connecting with global partners. Henlius looks forward to welcoming the BIO-2020 back to California where one of its R&D facilities is located in the Bay Area.
Henlius pressed forward with global footprint in recent years. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process. On the product side, HLX02 (trastuzumab injection), one of the major products, is the first biosimilar developed in China to enter a multi-jurisdictional Phase 3 clinical trial in China, Poland, Ukraine and the Philippines. HLX02 received a New Drug Application (NDA) acceptance from the NMPA in April, 2019. Moreover, with global quality standard, Henlius has proven track record of initiating strategic commercialisation collaborations with global leading pharmaceutical companies, which will enable Henlius to expeditiously capture market share through the established capabilities and partner resources. To this end, Henlius has entered into license and commercialisation agreements with multiple partners, including Accord, Cipla, Biosidus and Jacobson Medical. Henlius has entered into agreements for the licensing and commercialisation in over 82 jurisdictions and regions.